As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions. In the video series, Piotrowska discussed the following: · Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions · Testing for...
Apr 08, 2022•21 min•Season 2Ep. 21
As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer....
Apr 05, 2022•25 min•Season 2Ep. 20
As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly. In the video series, Kirkwood discussed the following: · Treatment Options for Melanoma · Considerations for Immunotherapy Use When Treating Melanoma · Monitoring Responses to Melanoma Therapy · Pseudoprogressio...
Apr 02, 2022•44 min•Season 2Ep. 19
As part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC). In the video series, Herbst discussed the following: · Treatment Options in Non–Small Cell Lung Cancer · Monitoring Response to Therapy in NSCLC · Role of ctDNA in Monitoring Treatment Res...
Mar 30, 2022•18 min•Season 2Ep. 18
This week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “ Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab .” The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large...
Mar 28, 2022•10 min•Season 1Ep. 45
CancerNetwork spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece titled, “ Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer .” Gong’s perspective focuses on an article published in the January issue of ONCOLOGY titled, “ Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based ...
Mar 14, 2022•13 min•Season 1Ep. 44
CancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy. Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for ...
Feb 28, 2022•15 min•Season 1Ep. 43
CancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “ Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma .” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma. In the conversation, Smith talked about what makes t...
Feb 14, 2022•13 min•Season 1Ep. 42
CancerNetwork spoke with Matthew Allaway, DO, founder and CEO of Perineologic, about a new prostate cancer biopsy technique that uses the transperineal approach to detect cancer in harder to reach areas of the prostate. Allaway touched on the American Cancer Society’s annual report that shows the rate of advanced-stage prostate cancer cases are increasing in recent years. He also detailed a companion study to that report, and walked through the specific details and benefits of this biopsy techni...
Jan 31, 2022•18 min•Season 1Ep. 41
This week, CancerNetwork closed the book on the year that was 2021. CancerNetwork spoke with Amy Comander, MD, co-medical director and director of breast oncology and cancer survivorship at Mass General Cancer Center, about some of the key developments and data to emerge from 2021 for patients with breast cancer, with a specific focus on the 2021 San Antonio Breast Cancer Symposium (SABCS). Not only did Comander detail important information from 2021 in the field of breast cancer, but she also t...
Jan 17, 2022•14 min•Season 1Ep. 40
As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR -mutated non–small cell lung cancer (NSCLC). In the video series, Bazhenova and Albrecht discussed the following: · ...
Jan 14, 2022•42 min•Season 2Ep. 17
This week, CancerNetwork spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. The director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affir...
Jan 03, 2022•27 min•Season 1Ep. 39
The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple P...
Dec 22, 2021•8 min•Season 2Ep. 16
Jun Gong, MD, discussed his perspective piece from the October issue of the journal ONCOLOGY , titled “ An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer .” Gong, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, commented on a review article previously examined on this podcast with Alexandra Sokolova, MD, titled “ Germline Testing in Prostate Cancer: When and Who to Test .” The r...
Dec 20, 2021•16 min•Season 1Ep. 38
In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy. Don’t for...
Dec 16, 2021•13 min•Season 2Ep. 15
This week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to inform patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, CEO and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform. The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing,...
Dec 06, 2021•20 min•Season 1Ep. 37
In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 ba...
Dec 02, 2021•14 min•Season 2Ep. 14
CancerNetwork looks at research from the October issue of the journal ONCOLOGY , titled “Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.” Lead author, Quirin Zangl, MD, from the Department of Neuroanesthesia, at the Christian Doppler Hospital in Salzburg, Austria, spoke in detail about the manuscript. The research featured 111 patients with urogenital carcinomas with the goal of evaluating comprehensive geriatric assessment tools to better guide these individuals. Patient...
Nov 22, 2021•9 min•Season 1Ep. 36
This week, CancerNetwork looks at an article from the October issue of the journal ONCOLOGY , titled “Germline Testing in Prostate Cancer: When and Who to Test.” CancerNetwork spoke with one of the authors of this article, Alexandra Sokolova, MD, an assistant professor at Oregon Health & Science University. Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing c...
Nov 08, 2021•18 min•Season 1Ep. 35
In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podc...
Nov 01, 2021•10 min•Season 2Ep. 13
As part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes. In the video series, Batlevi discussed the following: · Current Treatment Options and Considerations for Relapsed/Refractory Folli...
Oct 29, 2021•25 min•Season 2Ep. 12
This week, CancerNetwork spoke with Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President at Texas Oncology. Patt discussed the rise of telehealth during the COVID-19 pandemic, how clinicians can use these tools to help treat patients with cancer, and the role of telemedicine moving forward. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Oct 25, 2021•11 min•Season 1Ep. 34
As part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT...
Oct 19, 2021•36 min•Season 2Ep. 11
This episode features an examination of an article from the September issue of the journal ONCOLOGY , titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center. Gong detailed PSA’s role in prostate cancer, and other potential complementary bioma...
Oct 11, 2021•16 min•Season 1Ep. 33
This week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable. Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important ...
Sep 27, 2021•25 min•Season 1Ep. 32
CancerNetwork spoke with Quita Highsmith, Vice President and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in onc...
Sep 13, 2021•18 min•Season 1Ep. 31
For the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center. These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, th...
Aug 30, 2021•18 min•Season 2Ep. 10
As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies of relapsed/refractory follicular lymphoma. In the video series, Javier Munoz, MD, MS, FACP, discussed the following: · Current Treatment Options for Relapsed/Refractory Follicular Lymphoma · Factors in Choosing R/R FL Treatments · Treatment Options for Third-Line R/R FL · Use of Tazemetostat for R/R FL · Changes in Sequencing of R/R FL ...
Aug 25, 2021•20 min•Season 2Ep. 9
As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer. In the video series, Lee Schwartzberg, MD, FACP, discussed the following: · Extended Adjuvant Therapy for HR+ Breast Cancer · Molecular Biomarkers for HR+ Breast Cancer · Role of Genomic Testing in HR...
Aug 20, 2021•23 min•Season 2Ep. 8
This week's podcast focuses on a review article published in the June issue of the journal ONCOLOGY titled, “Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines.” CancerNetwork spoke with Anath Ravi, PhD, co-founder and chief science and clinical officer of MOLLI Surgical, and Randy Miles, MD, MPH, an assistant professor in the Department of Radiology and clinical service chief in the Division of Breast Imaging at Massachuse...
Aug 16, 2021•30 min•Season 1Ep. 30
